A randomised, placebo-controlled trial of Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia in chronic kidney disease

慢性肾脏疾病（CKD）贫血与健康状况不佳、死亡率增加和医疗费用高有关。刺激红细胞生成的药物通常用于治疗伴有贫血的CKD患者，然而一些患者对这些药物没有反应。HERO试验是一项临床试验，旨在测试药物Oxypentifylline治疗对红细胞刺激治疗无反应的CKD贫血患者的安全性、有效性和成本效益。

Anaemia in chronic kidney disease (CKD) is linked to poor health outcomes, increased death rates and high health care costs. Drugs that stimulate red blood cell production are routinely used to treat CKD patients with anaemia, however some patients do not respond to these drugs. The HERO trial is a clinical trial designed to test the safety, effectiveness and cost benefits of a drug Oxypentifylline, in treating CKD patients with anaemia that is unresponsive to red blood cell stimulating treatments.